Recently acquired HCV infection in men who have sex with men in Germany in the direct‐acting antivirals era and during the COVID ‐19 pandemic
Year: 2024
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Direct-acting antivirals (DAAs) are key to eliminating hepatitis C virus (HCV). In men who have sex with men (MSM) with HIV co-infection, recently acquired HCV infection is common. Sexual practices and reinfection rates may hamper micro-elimination despite high treatment rates. METHODS: The cohort included MSM with recently acquired HCV infection from 2014 to 2021. The patients' demographic, clinical, behavioural, and laboratory data and treatment and reinfection outcomes were documented. RESULTS: (IQR 527-835). The annual incidence of recently acquired HCV remained between 0.28% and 0.43% but dropped to 0.02% in 2021 during the COVID pandemic, almost reaching micro-elimination. The reinfection incidence was 15.5 per 100 patient-years (95% confidence interval 12.6-18.8), and reinfection was associated with the use of crystal methamphetamine (p = 0.032) and ketamine (p = 0.042). In total, 31.3% had multiple reinfections, and four reinfections occurred in users of pre-exposure prophylaxis. CONCLUSIONS: High treatment and cure rates did not lead to HCV elimination. A change in sexual behaviour, potentially imposed by COVID-19 restrictions, led to micro-elimination in the NoCo cohort. As recently acquired HCV is prevalent in MSM with and without HIV, surveillance is necessary to consolidate elimination goals.
Source: HIV Medicine
DOI: 10.1111/hiv.13651
Institutions: Inserm, Hôpitaux Universitaires Henri-Mondor, Infektionsmedizinisches Centrum Hamburg, Center for HIV and Hepatogastroenterology, University Hospital Münster, London School of Hygiene & Tropical Medicine, University of California San Diego, University of Bonn, German Center for Infection Research
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,950
Funder: Gilead Sciences
Award: G3222346142
OpenAlex ID: W4399185604
